Skip to content

The Impact of the COVID-19 Pandemic on Diabetes Management

The Impact of the COVID-19 Pandemic on Diabetes Management (CoDiaM)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04821921
Acronym
CoDiaM
Enrollment
1503
Registered
2021-03-30
Start date
2021-04-09
Completion date
2022-09-15
Last updated
2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus, Type 2 Diabetes

Brief summary

The CoDiaM study examines how diabetes management and outcomes are changing during the COVID-19 pandemic and whether these changes are influenced by socio-demographic factors, health literacy, self-efficacy and perceived social support.

Detailed description

The Covid-19 pandemic created new challenges for patients with diabetes and their treating physicians. In order to protect people from SARS-COV-2 infections, social contacts were reduced by restrictions on many areas of social life. As a side effect, these measures could have also led to changes in the self-management of patients with diabetes mellitus, such as lack of physical exercise, less healthy dietary behavior, and a reduced intensity of medical care. These possible changes may be associated with poorer control of blood glucose, cholesterol, and blood pressure. Therefore, the CoDiaM study will investigate how management and outcomes of diabetes are changing during the pandemic and identify associated factors. The study is based on data of patients treated in three GP practices specialized on diabetes treatment in Hamburg, Germany. Data collection will include a written patient survey and extraction of clinical data from patient records. The patient's survey includes sociodemographic data and validated instruments to assess diabetes self-management (DSMQ), health literacy (HLS-EU-Q16), self-efficacy (General Self-efficacy scale) and perceived social support (F-SozU K14). Data will be analyzed by descriptive statistics and multivariable, multilevel linear and logistic regression analyses adjusted for possible confounders and random effects on the practice level.

Interventions

OTHERNo intervention

Care as usual

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* being 18 years or older, and * having diabetes type 2 or type 1, and * having consulted the practice at least once in 2019 AND at least once in 2020

Exclusion criteria

* no capacity to consent (e.g. because of dementia) * insufficient German language skills to understand the questions in the questionnaire * not able to fill out the questionnaire (e.g. because of blindness) * gestational diabetes

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin A1c (HbA1c)01.01.2019 to 31.12.2021Data on outcome will be extracted from the GP's patient record

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026